The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

Many tumour cells carry mutations that increase signalling through the PI3K–AKT–mTOR (phosphoinositide 3-kinase–AKT–mammalian target of rapamycin) pathway. Although rapamycin (also known ...

K. O'Reilly et al., "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt," Cancer Res, 66:1500—8, 2006. (Cited in 95 papers) It's known that rapamycin inhibits ...